Usefulness of Adalimumab for Treating a Case of Intestinal Behcet's Disease With Trisomy 8 Myelodysplastic Syndrome
Intestinal Research
; : 166-169, 2015.
Artigo
em Inglês
| WPRIM (Pacífico Ocidental)
| ID: wpr-70046
Biblioteca responsável:
WPRO
ABSTRACT
Behcet's disease (BD) is a systemic vasculitis, while myelodysplastic syndrome (MDS) is a heterogeneous group of clonal hematologic disorders characterized by ineffective hematopoiesis. Some studies suggest a relationship between MDS and BD, especially intestinal BD, and trisomy 8 seems to play an important role in both diseases. There are several reports on patients with BD comorbid with MDS involving trisomy 8 that frequently have intestinal lesions refractory to conventional medical therapies. Tumor necrosis factor (TNF)-alpha is strongly involved in the pathophysiology of several autoimmune diseases such as rheumatoid arthritis, inflammatory bowel disease, and BD. In addition, TNF-alpha plays an important role in the pathophysiology of MDS by inhibiting normal hematopoiesis and inducing the programmed cell death of normal total bone marrow cells and normal CD34+ cells. Recent clinical reports demonstrate the favorable effect of TNF-alpha antagonists in patients with refractory intestinal BD and in those with MDS. We present the case of a patient with intestinal BD and MDS involving trisomy 8 who was successfully treated with adalimumab.
Texto completo:
Disponível
Base de dados:
WPRIM (Pacífico Ocidental)
Assunto principal:
Artrite Reumatoide
/
Doenças Autoimunes
/
Trissomia
/
Síndromes Mielodisplásicas
/
Células da Medula Óssea
/
Doenças Inflamatórias Intestinais
/
Síndrome de Behçet
/
Fator de Necrose Tumoral alfa
/
Morte Celular
/
Vasculite Sistêmica
Limite:
Humanos
Idioma:
Inglês
Revista:
Intestinal Research
Ano de publicação:
2015
Tipo de documento:
Artigo